L-Theanine for the treatment of obsessive-compulsive disorder

L-Theanine combination therapy with Fluvoxamine in moderate to severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N134

Enrollment

Registered

2020-12-12

Start date

2021-01-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Fluvoxamine tablet (Sobhan darou co.) 100 mg daily for the first 4 weeks and 200 mg daily for the next 6 weeks + L-Theanine (Institute of Medicinal Plants) tablet 1

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 60 years Diagnosis of moderate to severe OCD based on DSM-5 Score of >21 in Yale–Brown obsessive-compulsive scale (Y-BOCS)

Exclusion criteria

Exclusion criteria: Receiving any treatment up to 6 weeks before the start of the trial Presence of another psychiatric disorder

Design outcomes

Primary

Measure	Time frame
Severity of OCD symptoms. Timepoint: Baseline and weeks 5 and 10. Method of measurement: By Yale–Brown obsessive-compulsive scale (Y-BOCS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026